The present blog entry is rather long. This is however necessary, since a decision of a TBA-EPO is compared with a decision of a UPC-CFI LD Munich.
EP 2 493 466 B1 relates to a novel antitumoral use of cabazitaxel in the treatment of prostate cancer and has been claimed under Art 54(5) EPC.